Review
Virology
Li Fang, Junli Zhang, Fangfang Lv
Summary: Idiopathic CD4 + T lymphocytopenia (ICL) is a rare immunodeficiency syndrome. This article describes a case of disseminated cryptococcosis with varicella-zoster virus co-infection in a patient with ICL and reviews published reports. The pathophysiology and treatment of ICL remain poorly understood, highlighting the importance of increased awareness and early prevention of the disease.
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Review
Medicine, General & Internal
Athina-Maria Aloizou, Vasileios Siokas, Georgia Pateraki, Ioannis Liampas, Christos Bakirtzis, Zisis Tsouris, George Lazopoulos, Daniela Calina, Anca Oana Docea, Aristidis Tsatsakis, Dimitrios P. Bogdanos, Efthimios Dardiotis
Summary: Numerous studies have explored the potential of using multiple sclerosis disease-modifying drugs in the setting of ischemic stroke, yielding mostly positive results in animal studies. However, concerns on safety and other issues need to be addressed before implementing these drugs in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Zaki Al-Yafeai, Alexander Carvajal-Gonzalez, Hamzah Abduljabar, Muhammed Arvas, Shaan Patel, Neev Patel
Summary: This study comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-multiple sclerosis (MS) modifying therapies. CD20 and CD25 inhibitors were significantly associated with cardiovascular adverse events, while S1PR agonists showed fewer cardiac complications. These findings are important for personalized prescribing of MS agents based on the patient's cardiovascular profile.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Cell Biology
Diana Ferraro, Sara De Biasi, Anna Maria Simone, Riccardo Orlandi, Milena Nasi, Francesca Vitetta, Marcello Pinti, Marco Fogliani, Stefano Meletti, Andrea Cossarizza, Patrizia Sola
Summary: The study found that the proportions of Tregs and iNKT cells in the immunoregulatory cell networks changed in patients with Multiple Sclerosis, and FTY treatment may benefit patients by increasing cells with immunomodulatory potential.
Article
Multidisciplinary Sciences
Ben J. E. Raveney, Wakiro Sato, Daiki Takewaki, Chenyang Zhang, Tomomi Kanazawa, Youwei Lin, Tomoko Okamoto, Manabu Araki, Yukio Kimura, Noriko Sato, Terunori Sano, Yuko Saito, Shinji Oki, Takashi Yamamura
Summary: This study identified a subset of cytotoxic CD4(+) T cells expressing Eomes, known as Eomes(+) Th cells, that are crucially involved in the pathogenesis of secondary progressive MS (SPMS). Eomes levels could act as a biomarker to predict disease worsening in SPMS patients with over 80% accuracy. These findings have significant implications for SPMS biomarkers and potential therapeutic targets.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Clinical Neurology
Chiara Zanetta, Massimo Filippi, Lucia Moiola
Summary: Fingolimod has been approved for the treatment of relapsing MS in both adults and children. Real-world data from Italy confirms its effectiveness in pediatric patients with active disease, supporting its use as a therapeutic strategy for pediatric MS.
NEUROLOGICAL SCIENCES
(2021)
Review
Immunology
Zhao Zhao, Chun-Lai Ma, Zhi-Chun Gu, Yue Dong, Yang Lv, Ming-Kang Zhong
Summary: Fingolimod treatment in patients with multiple sclerosis is associated with a significant increase in infection risk, with a 16% higher risk compared to placebo and other active treatments. The risk is especially elevated for lower respiratory infections and herpes virus infections, and does not appear to be dose-dependent.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Emanuela Colombo, Cinthia Farina
Summary: Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that binds to specific G protein-coupled receptors expressed in various organs. Targeting S1P receptors with modulators has shown potential in treating neurological, autoimmune, and inflammatory disorders. These modulators induce lymphopenia and may have immunological effects beyond lymphocyte trafficking inhibition. They can also cross the blood-brain barrier and target CNS resident cells expressing S1P receptors. Understanding the role of S1P signaling in neuroimmunology has important implications for therapeutic approaches in other disease areas.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Neurosciences
G. Sferruzza, F. Clarelli, E. Mascia, L. Ferre, L. Ottoboni, M. Sorosina, S. Santoro, L. Moiola, V. Martinelli, G. Comi, F. Martinelli Boneschi, M. Filippi, P. Provero, Federica Esposito
Summary: The study investigated the gene transcriptional changes induced by FTY in monocytes of multiple sclerosis patients, revealing its major impact on genes associated with cell trafficking and immune cell activation.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Clinical Neurology
Valeria Koska, Moritz Foerster, Katja Brouzou, Ercan Arat, Philipp Albrecht, Orhan Aktas, Patrick Kuery, Sven G. Meuth, David Kremer
Summary: Discontinuation of Fingolimod can result in the rebound of tumefactive demyelinating lesions, requiring plasma exchange for remission, and long-term stabilization therapy to prevent disease reactivation.
FRONTIERS IN NEUROLOGY
(2021)
Review
Pharmacology & Pharmacy
Xin Wu, Tao Xue, Zilan Wang, Zhouqing Chen, Xuwei Zhang, Wei Zhang, Zhong Wang
Summary: The study evaluated the efficacy and safety of different doses of fingolimod in the treatment of RRMS, finding that 0.5 mg/d remains the optimal dose. Despite 1.25 mg/d being more than twice the dose of 0.5 mg/d, the effect size was almost similar between them, while 5 mg/d dose showed unsatisfactory efficacy and higher risk of adverse events.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Michela Ada Noris Ferilli, Laura Papetti, Massimiliano Valeriani
Summary: This paper presents three case histories of pediatric-onset multiple sclerosis patients and highlights the different uses of fingolimod in treatment, including escalation therapy and first-choice therapy. In all three cases, there was no further disease progression and no adverse events recorded approximately 1 year after initiating fingolimod treatment.
NEUROLOGICAL SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Claudia Fracasso, Alice Passoni, Laura Brambilla, Renato Mantegazza, Silvia Rossi, Marco Gobbi, Jacopo Lucchetti
Summary: This study developed a simple and rapid liquid chromatography-tandem mass spectrometry method for measuring the concentrations of Fingolimod and its active metabolite Fingolimod-Phosphate in human plasma. The method was accurate and precise, and can be used to evaluate the impact of drug and metabolite on inter-individual variability in clinical responses.
APPLIED SCIENCES-BASEL
(2022)
Article
Medicine, General & Internal
Naoto Ishimaru, Yohei Kanzawa, Hiroyuki Seto, Saori Kinami
Article
Medicine, General & Internal
Masahiro Kaneko, Naoto Ishimaru, Takahiro Nakajima, Yohei Kanzawa, Hiroyuki Seto, Saori Kinami
Article
Medicine, General & Internal
Naoto Ishimaru, Jun Ohnishi, Hiroyuki Seto, Yohei Kanzawa, Nobuya Sano, Saori Kinami
Summary: This case study illustrates a 23-year-old male patient presenting with fatigue, dry cough, and papules on tattoos, ultimately diagnosed with sarcoidosis caused by granulomas in the tattooed area. The patient was successfully treated with corticosteroids and delayed anti-viral therapy.
Article
Medicine, General & Internal
Hiroyuki Seto, Naoto Ishimaru, Jun Ohnishi, Yohei Kanzawa, Takahiro Nakajima, Toshio Shimokawa, Yuichi Imanaka, Saori Kinami
Summary: This study evaluated the effectiveness of a multidisciplinary team deprescribing intervention in reducing polypharmacy and potentially inappropriate medications in elderly orthopedic inpatients. The intervention resulted in a significant reduction in the number of prescribed medicines and potentially inappropriate medications, as well as a decrease in certain adverse events.
Article
Medicine, General & Internal
Masahiro Kaneko, Naoto Ishimaru, Toshio Shimokawa, Takahiro Nakajima, Yohei Kanzawa, Hiroyuki Seto, Saori Kinami
Summary: This study aimed to investigate the impact of the distance between the skin and the renal pelvis on the detection of costovertebral angle (CVA) tenderness in patients with acute focal bacterial nephritis (AFBN). Retrospective analysis was conducted on patients diagnosed with AFBN between April 2013 and June 2019. The results showed that among skin-to-renal pelvis distance (SPD), body mass index (BMI), and age, only SPD was a useful predictor of CVA tenderness, with 66mm being the optimal cutoff point.
SOUTHERN MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Naoto Ishimaru, Yohei Kanzawa, Takahiro Nakajima, Hiroyuki Seto, Masayuki Ando, Saori Kinami
Summary: A 22-year-old Japanese woman presented with appendicitis complicated by Chlamydia trachomatis-induced Fitz-Hugh-Curtis syndrome and cervicitis. Despite challenges in the differential diagnosis, successful treatment was achieved through noncontrast CT and laparoscopic appendectomy.
JOURNAL OF GENERAL AND FAMILY MEDICINE
(2021)
Article
Orthopedics
Jun Ohnishi, Naoto Ishimaru, Hiroyuki Seto, Yohei Kanzawa, Saori Kinami
JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION
(2020)
Meeting Abstract
Health Care Sciences & Services
Hiroyuki Seto, Toshio Shimokawa, Jun Ohnishi, Yohei Kanzawa, Kei Kawano, Takahiro Nakajima, Naoto Ishimaru, Saori Kinami, Yuichi Imanaka
JOURNAL OF GENERAL INTERNAL MEDICINE
(2020)
Article
Medicine, General & Internal
Naoto Ishimaru, Saori Kinami, Toshio Shimokawa, Hiroyuki Seto, Yohei Kanzawa
JOURNAL OF GENERAL AND FAMILY MEDICINE
(2020)
Article
Rheumatology
Masaki Kobatake, Naoto Ishimaru, Yohei Kanzawa, Hiroyuki Seto, Saori Kinami
EUROPEAN JOURNAL OF RHEUMATOLOGY
(2019)
Meeting Abstract
Health Care Sciences & Services
Yohei Kanzawa, Hiroyuki Seto, Naoto Ishimaru, Saori Kinami
JOURNAL OF GENERAL INTERNAL MEDICINE
(2018)
